



**HIV Seroconversion Panel Donor No. 68262  
Part Number: HIV9029**

**Donor Demographics:** Donor source plasma was collected from a U.S. licensed blood collection facility.  
Donor was un-treated and asymptomatic throughout the collection period.

PANEL MEMBER	DATE OF DRAW	CHIRON HIV-1 bDNA	ABBOTT HIV-1 p24 Ag	COULTER HIV-1 p24 Ag	ROCHE ELECSYS HIV p24Ag	ABBOTT AxSYM HIV AB ½ EIA	ABBOTT HIV AB ½ EIA rDNA	ABBOTT HIV AB ½ EIA rDNA 3 <sup>rd</sup> Generation	ABBOTT MUREX HIV Ab ½ + O 3 <sup>rd</sup> Generation
		TEST DATE: 10/26/1999	TEST DATE: 6/16/1999	TEST DATE: 8/5/1999	TEST DATE: 6/10/1999	TEST DATE: 7/14/1999	TEST DATE: 5/13/1999	TEST DATE: 6/14/1999	TEST DATE: UNK
9029-01	07/27/98	<50	0.44	0.490	0.50	0.26	0.207	0.23	0.284
9029-02	07/29/98	<50	0.38	0.392	0.34	0.27	0.174	0.25	0.313
9029-03	08/05/98	<50	0.51	0.392	0.36	0.25	0.149	0.25	0.356
9029-04	08/07/98	<50	0.39	0.392	0.37	0.29	0.198	0.25	0.400
9029-05	08/12/98	<50	0.39	0.686	0.39	7.15	0.182	6.33	0.281
9029-06	08/14/98	<50	0.38	0.686	0.31	0.22	0.190	0.26	0.263
9029-07	08/19/98	<50	0.37	0.588	0.37	0.23	0.165	0.25	0.272
9029-08	08/21/98	<50	0.34	0.686	0.37	0.19	0.190	0.22	0.263
9029-09	08/26/98	<50	0.38	0.882	0.40	0.21	0.174	0.22	0.300
9029-10	08/28/98	<50	0.43	0.882	0.33	0.23	0.207	0.26	0.275
9029-11	09/02/98	3594	0.48	1.078	0.48	0.23	0.157	0.24	0.325
9029-12	09/10/98	>500000	8.37	32.353	46.97	0.27	0.174	0.27	0.578

PANEL MEMBER	ABBOTT HIV AB ½ EIA rDNA IMx	ABBOTT MUREX SUDS ANTI-HIV-1	ABBOTT PRISM ANTI-HIV ½	BIOMERIEUX ORGANON VIRNOSTIKA HIV-1 MICROELISA SYSTEM	BIO-RAD NOVAPATH HIV-1 IMMUNOBLOT	BIOTEST ANTI-HIV ½	BIOTEST ANTI-HIV-1 TETRA ELISA
	TEST DATE: 12/7/1999	TEST DATE: 7/21/1999	TEST DATE: 7/15/1999	TEST DATE: 6/18/1999	TEST DATE: UNK	TEST DATE: 6/9/1999	TEST DATE: 6/8/1999
9029-01	0.43	0.20	0.33	0.326	NEGATIVE	0.03	0.11
9029-02	0.41	0.20	0.25	0.297	NEGATIVE	0.01	0.12
9029-03	0.47	0.20	0.34	0.267	NEGATIVE	0.02	0.17
9029-04	0.45	0.31	0.31	0.297	NEGATIVE	0.02	0.15
9029-05	11.27	3.45	11.30	0.267	NEGATIVE	0.08	0.16
9029-06	0.35	0.18	0.23	0.267	NEGATIVE	0.01	0.15
9029-07	0.32	0.17	0.21	0.237	NEGATIVE	0.02	0.17
9029-08	0.36	0.23	0.21	0.237	NEGATIVE	0.03	0.17
9029-09	0.39	0.18	0.23	0.237	NEGATIVE	0.00	0.13
9029-10	0.35	0.16	0.21	0.237	NEGATIVE	0.02	0.15
9029-11	0.35	0.16	0.22	0.237	NEGATIVE	0.01	0.15
9029-12	0.36	0.18	0.36	0.267	NEGATIVE	0.01	0.45

**Notes on Data:**

1. This panel is for **Research Use Only. Not for use in diagnostic procedures.**
2. Data is generated at ZeptoMetrix™ LLC and by our Laboratory Partners in the United States and Europe.
3. All specimens collected in this longitudinal series are unadulterated 4% sodium citrated plasma samples collected from a single donor in the United States.
4. No preservatives have been added.
5. All material has been tested and found negative for HBsAg, Anti HCV by FDA cleared tests.

ZeptoMetrix LLC • 25 Kenwood Circle, Franklin, MA 02038 • Tel (508) 553-5800 • Fax (508) 520-1525  
This Product was manufactured in a facility which has a Quality Management System that is ISO 13485 certified.  
For Customer Support, please visit [www.zeptometrix.com](http://www.zeptometrix.com) or email [zepto.customerservice@antylia.com](mailto:zepto.customerservice@antylia.com)

# ZeptoMetrix®

## HIV Seroconversion Panel Donor No. 68262 Part Number: HIV9029

**Donor Demographics:** Donor source plasma was collected from a U.S. licensed blood collection facility.  
Donor was un-treated and asymptomatic throughout the collection period.

PANEL MEMBER	DADE BEHRING ENZYGNOST ANTI-HIV ½ PLUS TEST DATE: 6/8/1999	GENETICS SYSTEMS HIV ½ PEPTIDE EIA TEST DATE: 6/10/1999	ORTHO ANTI-HIV ½ ENHANCED ELISA TEST DATE: 6/21/1999	BIOMERIEUX ORGANON VIRNOSTIKA HIV UNIFORM II PLUS O TEST DATE: 6/9/1999	SANOFI GENSCREEN ANTI-HIV ½ TEST DATE: 6/21/1999	ABBOTT PRISIM HIV Ag/Ab COMBO 4 <sup>TH</sup> Generation TEST DATE: UNK	ABBOTT MUREX HIV-1 Ab/Ag COMBO 4 <sup>TH</sup> Generation TEST DATE: UNK
9029-01	0.13	0.257	0.04	0.23	0.05	0.07	0.269
9029-02	0.17	0.257	0.04	0.42	0.06	0.18	0.244
9029-03	0.15	0.143	0.04	0.45	0.07	0.12	0.234
9029-04	0.16	0.114	0.03	0.42	0.08	0.20	0.234
9029-05	5.81	0.229	0.04	0.40	0.07	0.09	0.249
9029-06	0.12	0.371	0.06	0.42	0.09	0.07	0.335
9029-07	0.13	0.286	0.04	0.40	0.10	0.07	0.269
9029-08	0.12	0.229	0.06	0.44	0.10	0.08	0.264
9029-09	0.12	0.257	0.03	0.43	0.11	0.09	0.269
9029-10	0.12	0.229	0.04	0.31	0.13	0.29	0.244
9029-11	0.11	0.171	0.04	0.47	0.17	0.14	0.279
9029-12	0.14	0.371	0.76	0.52	0.96	26.76	16.624

PANEL MEMBER	ABBOTT ARCHITECT HIV Ag/Ab COMBO 4 <sup>TH</sup> Generation TEST DATE: UNK	BIO-RAD BioPlex 2200 HIV Ag-Ab 5 <sup>th</sup> Generation TEST DATE: UNK	BIO-RAD BioPlex 2200 HIV-1 Ag 5 <sup>th</sup> Generation TEST DATE: UNK	BIO-RAD BioPlex 2200 HIV-1 Ab 5 <sup>th</sup> Generation TEST DATE: UNK	ORTHO VITROS ECi ANTI-HIV ½ TEST DATE: 8/30/2018
9029-01	0.07	0.09	0.09	0.04	0.11
9029-02	0.07	0.03	0.02	0.01	0.10
9029-03	0.10	0.03	0.03	0.02	0.11
9029-04	0.17	0.10	0.10	0.05	0.09
9029-05	0.09	0.08	0.08	0.03	0.09
9029-06	0.10	0.09	0.09	0.01	0.09
9029-07	0.10	0.06	0.06	0.01	0.12
9029-08	0.19	0.10	0.10	0.06	0.11
9029-09	0.10	0.07	0.06	0.07	0.10
9029-10	0.10	0.06	0.06	0.05	0.11
9029-11	0.19	0.24	0.24	0.03	0.11
9029-12	36.89	121.68	121.68	0.08	0.56

### Notes on Data:

1. This panel is for **Research Use Only. Not for use in diagnostic procedures.**
2. Data is generated at ZeptoMetrix™ LLC and by our Laboratory Partners in the United States and Europe.
3. All specimens collected in this longitudinal series are unadulterated 4% sodium citrated plasma samples collected from a single donor in the United States.
4. No preservatives have been added.
5. All material has been tested and found negative for HBsAg, Anti HCV by FDA cleared tests.

ZeptoMetrix LLC • 25 Kenwood Circle, Franklin, MA 02038 • Tel (508) 553-5800 • Fax (508) 520-1525  
This Product was manufactured in a facility which has a Quality Management System that is ISO 13485 certified.  
For Customer Support, please visit [www.zeptometrix.com](http://www.zeptometrix.com) or email [zepto.customerservice@antylia.com](mailto:zepto.customerservice@antylia.com)

PIHIV9029 Rev05  
Effective Date: 10/26/2021